165 related articles for article (PubMed ID: 25720061)
1. Ceramide and sphingosine in pulmonary infections.
Seitz AP; Grassmé H; Edwards MJ; Pewzner-Jung Y; Gulbins E
Biol Chem; 2015 Jun; 396(6-7):611-20. PubMed ID: 25720061
[TBL] [Abstract][Full Text] [Related]
2. Ceramide in bacterial infections and cystic fibrosis.
Grassmé H; Becker KA; Zhang Y; Gulbins E
Biol Chem; 2008 Nov; 389(11):1371-9. PubMed ID: 18783339
[TBL] [Abstract][Full Text] [Related]
3. Lack of Sphingosine Causes Susceptibility to Pulmonary Staphylococcus Aureus Infections in Cystic Fibrosis.
Tavakoli Tabazavareh S; Seitz A; Jernigan P; Sehl C; Keitsch S; Lang S; Kahl BC; Edwards M; Grassmé H; Gulbins E; Becker KA
Cell Physiol Biochem; 2016; 38(6):2094-102. PubMed ID: 27184795
[TBL] [Abstract][Full Text] [Related]
4. β1-Integrin Accumulates in Cystic Fibrosis Luminal Airway Epithelial Membranes and Decreases Sphingosine, Promoting Bacterial Infections.
Grassmé H; Henry B; Ziobro R; Becker KA; Riethmüller J; Gardner A; Seitz AP; Steinmann J; Lang S; Ward C; Schuchman EH; Caldwell CC; Kamler M; Edwards MJ; Brodlie M; Gulbins E
Cell Host Microbe; 2017 Jun; 21(6):707-718.e8. PubMed ID: 28552668
[TBL] [Abstract][Full Text] [Related]
5. Interferon regulatory factor 8 regulates expression of acid ceramidase and infection susceptibility in cystic fibrosis.
Gardner AI; Wu Y; Verhaegh R; Liu Y; Wilker B; Soddemann M; Keitsch S; Edwards MJ; Haq IJ; Kamler M; Becker KA; Brodlie M; Gulbins E
J Biol Chem; 2021; 296():100650. PubMed ID: 33839155
[TBL] [Abstract][Full Text] [Related]
6. Sphingolipids as targets for inhalation treatment of cystic fibrosis.
Becker KA; Riethmüller J; Seitz AP; Gardner A; Boudreau R; Kamler M; Kleuser B; Schuchman E; Caldwell CC; Edwards MJ; Grassmé H; Brodlie M; Gulbins E
Adv Drug Deliv Rev; 2018 Aug; 133():66-75. PubMed ID: 29698625
[TBL] [Abstract][Full Text] [Related]
7. Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease.
Brodlie M; McKean MC; Johnson GE; Gray J; Fisher AJ; Corris PA; Lordan JL; Ward C
Am J Respir Crit Care Med; 2010 Aug; 182(3):369-75. PubMed ID: 20395562
[TBL] [Abstract][Full Text] [Related]
8. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis.
Teichgräber V; Ulrich M; Endlich N; Riethmüller J; Wilker B; De Oliveira-Munding CC; van Heeckeren AM; Barr ML; von Kürthy G; Schmid KW; Weller M; Tümmler B; Lang F; Grassme H; Döring G; Gulbins E
Nat Med; 2008 Apr; 14(4):382-91. PubMed ID: 18376404
[TBL] [Abstract][Full Text] [Related]
9. Ceramide in cystic fibrosis.
Grassmé H; Riethmüller J; Gulbins E
Handb Exp Pharmacol; 2013; (216):265-74. PubMed ID: 23563661
[TBL] [Abstract][Full Text] [Related]
10. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis.
Guilbault C; De Sanctis JB; Wojewodka G; Saeed Z; Lachance C; Skinner TA; Vilela RM; Kubow S; Lands LC; Hajduch M; Matouk E; Radzioch D
Am J Respir Cell Mol Biol; 2008 Jan; 38(1):47-56. PubMed ID: 17656682
[TBL] [Abstract][Full Text] [Related]
11. Ceramide in Pseudomonas aeruginosa infections and cystic fibrosis.
Becker KA; Grassmé H; Zhang Y; Gulbins E
Cell Physiol Biochem; 2010; 26(1):57-66. PubMed ID: 20502005
[TBL] [Abstract][Full Text] [Related]
12. Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa.
Pewzner-Jung Y; Tavakoli Tabazavareh S; Grassmé H; Becker KA; Japtok L; Steinmann J; Joseph T; Lang S; Tuemmler B; Schuchman EH; Lentsch AB; Kleuser B; Edwards MJ; Futerman AH; Gulbins E
EMBO Mol Med; 2014 Sep; 6(9):1205-14. PubMed ID: 25085879
[TBL] [Abstract][Full Text] [Related]
13. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis.
Becker KA; Riethmüller J; Lüth A; Döring G; Kleuser B; Gulbins E
Am J Respir Cell Mol Biol; 2010 Jun; 42(6):716-24. PubMed ID: 19635928
[TBL] [Abstract][Full Text] [Related]
14. The Anti-Infectious Role of Sphingosine in Microbial Diseases.
Wu Y; Liu Y; Gulbins E; Grassmé H
Cells; 2021 May; 10(5):. PubMed ID: 34064516
[TBL] [Abstract][Full Text] [Related]
15. Clinical Development of Sphingosine as Anti-Bacterial Drug: Inhalation of Sphingosine in Mini Pigs has no Adverse Side Effects.
Carstens H; Schumacher F; Keitsch S; Kramer M; Kühn C; Sehl C; Soddemann M; Wilker B; Herrmann D; Swaidan A; Kleuser B; Verhaegh R; Hilken G; Edwards MJ; Dubicanac M; Carpinteiro A; Wissmann A; Becker KA; Kamler M; Gulbins E
Cell Physiol Biochem; 2019; 53(6):1015-1028. PubMed ID: 31854953
[TBL] [Abstract][Full Text] [Related]
16. IKK NBD peptide inhibits LPS induced pulmonary inflammation and alters sphingolipid metabolism in a murine model.
von Bismarck P; Winoto-Morbach S; Herzberg M; Uhlig U; Schütze S; Lucius R; Krause MF
Pulm Pharmacol Ther; 2012 Jun; 25(3):228-35. PubMed ID: 22469869
[TBL] [Abstract][Full Text] [Related]
17. Glucosylceramide Critically Contributes to the Host Defense of Cystic Fibrosis Lungs.
Kovacic B; Sehl C; Wilker B; Kamler M; Gulbins E; Becker KA
Cell Physiol Biochem; 2017; 41(3):1208-1218. PubMed ID: 28427052
[TBL] [Abstract][Full Text] [Related]
18. CFTR-dependent susceptibility of the cystic fibrosis-host to Pseudomonas aeruginosa.
Grassmé H; Becker KA; Zhang Y; Gulbins E
Int J Med Microbiol; 2010 Dec; 300(8):578-83. PubMed ID: 20951085
[TBL] [Abstract][Full Text] [Related]
19. Acid Ceramidase Rescues Cystic Fibrosis Mice from Pulmonary Infections.
Becker KA; Verhaegh R; Verhasselt HL; Keitsch S; Soddemann M; Wilker B; Wilson GC; Buer J; Ahmad SA; Edwards MJ; Gulbins E
Infect Immun; 2021 Jan; 89(2):. PubMed ID: 33139382
[TBL] [Abstract][Full Text] [Related]
20. Lipids in cystic fibrosis.
Becker KA; Henry B; Ziobro R; Riethmüller J; Gulbins E
Expert Rev Respir Med; 2011 Aug; 5(4):527-35. PubMed ID: 21859272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
